Table 1.
Human anti-TIM-3 antibodies in development.
| Anti-TIM-3 Antibodies | Current Development | References |
|---|---|---|
| LY3321367 (Eli Lilly; Indianapolis, IN, USA) |
Phase 1 trial in patients with relapsed/refractory solid tumor, alone or in combination with an anti-PD-L1 mAb. NCT03099109 * | [66,72] |
| Sabatolimab (MBG453, Novartis, Basel, Switzerland) |
Fast track designation by US FDA for the treatment of patients with myelodysplastic syndromes (MDS) | [73] |
| Phase 1 trial in patients with advanced solid tumor, alone or in combination with anti-PD-1 spartalizumab. | [63] | |
| Phase 1 trial in patients with Acute Myeloid Leukemia (AML). NCT04812548, NCT04623216, NCT04878432, NCT04150029 * | [74] | |
| BMS-986258 (ONO 7807, BMS, Lawrenceville, NJ, USA) |
Fully human anti-TIM-3 mAb, tested in combination with anti-PD-1 nivolumab in patients with advanced solid tumors (Phase 1). NCT03446040 * | |
| Cobolimab (TSR-022, GSK, Brentford, UK) |
Anti-TIM-3 mAb in combination with anti-PD-1 in patients with liver cancer or with a melanoma (Phase 1). NCT04655976, NCT03680508, NCT04139902, NCT02817633 * | |
| Sym023 (Symphogen; Ballerup, Denmark) |
Fully human anti-TIM-3 mAb, in patients with advanced solid tumor malignancies or lymphomas (Phase 1). NCT03489343 * | |
| INCAGN02390 (Incyte, Agenus; Wilmington, DE, USA) |
Phase 1 study to determine the safety, tolerability, and preliminary efficacy in participants with advanced malignancies. Fully human Fc-engineered IgG1k. NCT03652077, NCT04370704. | [75] |
| RO7121661 (Roche; Basel, Switzerland) |
Anti-PD-1/TIM-3 bispecific mAbs, tested in patients with advanced and/or metastatic solid tumors (Phase 1). NCT03708328 * | |
| BGB-A425 (BeiGene Ltd., Beijing, China) |
Humanized anti-TIM-3 mAb, in combination with anti-PD-1 mAb tislelizumab, in patients with advanced solid tumors (phase I/II trial). NCT03744468 * | [76] |
| M6903 | Fully human anti-TIM-3 mAb, without effector function, which blocks binding of TIM-3 to the 3 ligands phosphatidylserine, CEACAM1, and Gal-9. Experimental laboratories studies. | [65] |
| F38.2E2 | Anti-human TIM-3 antibody capable of blocking binding of TIM-3 to phosphatidylserine and CEACAM1. Experimental tool. | [77] |
* ClinicalTrials.gov Identifier.